Monocyte expression of Toll-like receptor-4 in patients with stable angina undergoing percutanoeus coronary intervention

Iranian Journal of Immunology

Volumn 9, Issue 3, 2012, Pages 149-158

  Bagheri, Bahador ^a   Sohrabi, Bahram ^b   Movassaghpur, Aliakbar ^c   Mashayekhi, Siminozar ^d   Garjani, Afagh ^a   Shokri, Mehriar ^b   Noori, Mohammad ^b   Garjani, Alireza ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d Faculty of Pharmacy   (Iran)

Author keywords

Inflammation; Percutanoeus Coronary Intervention; Stable Angina; Toll Like Receptor 4

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CD14 ANTIGEN; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCERYL TRINITRATE; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1BETA; NITRATE; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; WARFARIN;

ADULT; ARTICLE; BLOOD SAMPLING; CELL DIFFERENTIATION; CLINICAL ARTICLE; CORRELATION ANALYSIS; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IRAN; MALE; MONOCYTE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STABLE ANGINA PECTORIS;

AGED; ANGINA, STABLE; ANGIOPLASTY; ANTIGENS, CD14; CELLS, CULTURED; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-1; MALE; MIDDLE AGED; MONOCYTES; PROGNOSIS; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84867824229     PISSN: 17351383     EISSN: 1735367X     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Glass CK, Witztum JL. Atherosclerosis. The road ahead. Cell. 2001; 104:503-16.
2. Shah PK. Mechanisms of plaque vulnerability and rupture. J Am Coll Cardiol. 2003; 41:15-22.
3. Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM, et al. Lack of Toll-like r eceptor 4 or myeloid differentiationfactor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci USA. 2004; 101:10679-84.
4. Stemme S, Faber B, Holm J, Wiklund O, Witztumi JL, Hansson GK. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci USA. 1995; 92:3893-7.
5. Ross R. atherosclerosis-an inflammatory disease. N Eng J Med. 1999; 340:115-26.
6. Takeda K, Akira S. Toll like receptors in innate immunity. Int Immunol. 2005; 17:1-14.
7. Takeda K, Akira S. Roles of Toll-like receptors in innate immune responses. Genes Cells. 2001; 11:733-42.
8. Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ. Expression of Toll-Like Receptors Human Atherosclerotic Lesions: A Possible Pathway for Plaque Activation. Circulation. 2002; 105:1158-61.
9. Yang J, Jin LY, Ding JW, Zhou YQ, Yang J, Rui-Yang, et al. Expression of Toll-like receptor 4 on peripheral blood mononuclear cells and its effects on patients with acute myocardial infarction treated with thrombolysis. Arch Med Res. 2010; 41:423-9.
10. Jerssmann HP. Time to abandon dogma: CD14 is expressed by non-myeloid lineage cells. Immunol Cell Biol. 2005; 83:462-7.
11. Tsan MF, Gao B. Endogenous ligands of Toll-like receptors. J Leukoc Biol. 2004; 76:514-9.
12. Palsson-McDermott EM, O'Neill LA. Signal transduction by the lipopolysaccharide receptor, Toll-like receptor-4. Immunology. 2004; 113:153-62.
13. Ohashi K, Burkart V, Flohé S, Kolb H. Cutting Edge: Heat Shock Protein 60 Is a Putative Endogenous Ligand of the Toll-Like Receptor-4 Complex. J Immunol. 2000;164:558-61.
14. Miller YL, Viriyakosol S, Binder CJ, Feramisco JR, Kirkland TN, Witztum JL. Minimally Modified LDL Binds to CD14, Induces Macrophage Spreading via TLR4/MD-2, and Inhibits Phagocytosis of Apoptotic Cells. J Biol Chem. 2003; 278:1561-8.
15. Xu XH, Shah PK, Faure E, Equils O, Thomas L, Fishbein MC, et al. Toll-Like Receptor-4 Is Expressed by Macrophages in Murine and Human Lipid-Rich Atherosclerotic Plaques and Upregulated by Oxidized LDL. Circulation. 2001; 104:3103-8.
16. Schnare M, Barton GM, Holt AC, Takeda K, Akira S, Medzhitov R. Toll-like receptors control activation of adaptive immune responses. Nat Immunol. 2001; 2:947-50.
17. Frantz S, Bauersachs J. Toll-like receptors: emerging therapeutic targets for heart failure. Heart Metab. 2010; 47:19-22.
18. Methe H, Brunner S, Wiegand D, Nabauer M, Koglin J, Edelman ER. Enhanced T-Helper-1 Lymphocyte Activation Patterns in Acute Coronary Syndromes. J Am Coll Cardiol. 2005; 45:1939-45.
19. Methe H, Kim JO, Kofler S, Weis M, Nabauer M, Koglin J. Expansion of Circulating Toll-Like Receptor 4-Positive Monocytes in Patients with Acute Coronary Syndrome. Circulation. 2005; 111:2654-61.
20. Irwin MW, Mak S, Mann DL, Qu R, Penninger JM, Yan A, et al. Tissue expression and immunolocalization of tumor necrosis factor-α in postinfarction dysfunctional myocardium. Circulation.1999; 99:1492-8.
21. Patti G, Mega S, Pasceri V, Nusca A, Giorgi G, Zardi EM, et al. Interleukin-1 receptor antagonist levels correlate with extent of myocardial loss in patients with acute myocardial infarction. Clin Cardiol. 2005; 28:193-6.
22. Rihal CS, Raco DL, Gersh BJ, Yusuf S. Indications for coronary artery bypass surgery and percutaneous coronary intervention in chronic stable angina: review of the evidence and methodological considerations. Circulation. 2003; 108:2439-45.
23. Parisi AF, Folland ED, Hartigan P. A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease: Veterans Affairs ACME Investigators. N Engl J Med. 1992; 326:10-6.
24. Imler JL, Hoffmann JA. Toll and Toll-like proteins: an ancient family of receptor signaling infection. Rev Immunogenet. 2000; 2:294-304.
25. Akira S. Mammalian Toll-like receptors. Curr Opin Immunol. 2003; 15:5-11.
26. Wick G, Knoflach M, Xu Q. Autoimmune and inflammatory mechanism in atherosclerosis. Annu Rev Immunol. 2004; 22:361-403.
27. Heine H, Lein E. Toll-like receptors and their function in innate and adaptive immunity. Int Arch Allergy Immunol. 2003; 130:180-92.
28. Yang J, Yang J, Ding JW, Chen LH, Wang YL, Li S, et al. Sequential expression of TLR4 and its effects on the myocardium of rats with myocardial ischemia-reperfusion injury. Inflammation. 2008; 31:304-12.
29. Ishikawa Y, Satoh M, Itoh T, Minami Y, Takahashi Y, Akamura M. Local expression of Toll-like receptor 4 at the site of ruptured plaque in patients with acute myocardial infarction. Chin Sci. 2008; 115:133-40.
30. Hezi-Yamit A, Sullivan C, Wong J, David L, Chen M, Cheng P, et al. Novel high-throughput polymer bio-compatibility screening designed for SAR (structure-activity relationship): application for evaluating polymer coatings for cardiovascular drug-eluting stents. Comb Chem High Throughput Screen. 2009;12:664-76.
31. Johnson GB, Brunn GJ, Kodaira Y, Platt JL. Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. J Immunol. 2002; 168:5233-9.
32. Rabenstein DL. Heparin and heparin sulfate: structure and function. Nat Prod Rep. 2002; 19:312-31.
33. Fukuda D, Shimada K, Tanaka A, Kawarabayashi T, Yoshiyama M, Yoshikawa J. Circulating monocytes and in-stent neointima after coronary stent implantation. J Am Coll Cardiol. 2004; 43:18-23.
34. Inoue T, Komoda H, Kotooka N, Morooka T, Fujimatsu D, Hikichi Y, et al. Increased circulating platelet-derived microparticles are associated with stent-induced vascular inflammation. Atherosclerosis. 2008; 196:469-76.
35. Toutouzas K, Colombo A, Stefanadis C. Inflammation and restenosis after percutaneous coronary interventions. Eur Heart J. 2004; 25: 1679-87.
36. Versteeg D, Hoefer IE, Schoneveld AH, De Kleijin DP, Busser E, Strijider C, et al. Monocyte toll-like receptor 2 and 4 response and expression following percutaneous coronary intervention: association between lesion stenosis and fractional flow reserve. Heart. 2008; 94:770-6.
37. Methe H, Kim JO, Kofler S, Nabauer M, Weis M. Statins Decrease Toll-Like Receptor 4 Expression and Downstream Signaling in Human CD14+ Monocytes. Arterioscler Thromb Vasc Biol. 2005; 25:1439-45.
38. Földesa G, Haehlinga S, Okonkoa D, Jankowskaa EA, Poole-Wilson PA, Anker SD. Fluvastatin reduces increased blood monocyte Toll-like receptor 4 expression in whole blood from patients with chronic heart failure. Int J Cardiol. 2008; 124:80-5.
39. Anker SD, Coats AJ. (2002) How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol. 2002; 86:123-30.
40. Mahaffey KW, Granger CB, Nicolau JC, Ruzyllo W, Weaver WD, Theroux P, et al. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. Circulation. 2003; 108: 1176-83.
41. Hoefer IE, van Royen N, Rectenwald JE, Bray EJ, Abouhamze Z, Moldawer LL. Direct evidence for tumor necrosis factor-alpha signaling in arteriogenesis. Circulation. 2002; 105:1639-41.
42. Yoshida J, Ohmori K, Takeuchi H, Shinomiya K, Namba T, Kondo L, et al. Treatment of ischemic limbs on local recruitment of vascular endothelial growth factor-producing inflammatory cells with ultrasonic microbubble destruction. J Am Coll Cardiol. 2005; 46:899-905.
43. Grote K, Schütt H, Schieffer B. Toll-like receptors in angiogenesis. ScientificWorldJournal. 2011; 11:981-91.